



## 22 Abstract

23 **Introduction:** Pediatric acute lymphoblastic leukemia (ALL) has cure rates exceeding 90%, while  
24 adult ALL has a 3-year survival rate of only 40–50%. Adolescents and young adults (AYAs) face  
25 unique challenges due to age-related factors and high-risk disease features. Although pediatric-  
26 inspired regimens improve survival, intensive chemotherapy increases susceptibility to severe  
27 infections.

28 **Methods:** A retrospective analysis was conducted on AYA-ALL patients treated at Chiang Mai  
29 University Hospital from 1 January 2007 to 31 December 2023. Patients were classified into  
30 pediatric-inspired (TPOG) or adult regimens (Hyper-CVAD or GMALL). Infections were  
31 categorized as clinically documented infections (CDI) or microbiologically documented  
32 infections (MDI). Multivariate logistic regression was used to identify infection risk factors.

33 **Results:** Among 94 patients (62.8% male; median age 22.9 years), 56.4% received TPOG and  
34 43.6% received adult regimens. Infectious complications occurred in 79.8% of patients, with  
35 higher rates in the adult regimen group (90.2% vs. 71.7%,  $p = 0.03$ ). CDI was more frequent in  
36 the adult group (73.4% vs. 52.8%,  $p = 0.04$ ), while fungal infections were more common in the  
37 TPOG group (26.4% vs. 9.8%,  $p = 0.04$ ). Adult regimens significantly increased infection risk  
38 (OR 3.55; 95% CI 1.02–12.36,  $p = 0.04$ ). Infection rates peaked during induction (47.8%) and  
39 consolidation (51.8%). During induction, MDI was lower in the adult group (21% vs. 79%,  $p =$   
40 0.01), while CDI was higher during consolidation (69% vs. 30%,  $p < 0.01$ ). Gram-negative  
41 bacteria were the most common pathogens (85%), particularly *E. coli* (27%) and *Salmonella* spp.  
42 (21%). Fungal infections affected 19.1% of patients, with invasive pulmonary aspergillosis being  
43 the most common (11.7%).

44 **Conclusion:** AYA-ALL patients are highly susceptible to infections, especially those receiving  
45 adult regimens. Fungal infections were notably more common in patients on the TPOG regimen.  
46 Strengthening infection prevention and providing early treatment are vital for improving patient  
47 outcomes.

48 **Keywords:** Acute lymphoblastic leukemia, Adolescents and young adults, Infectious  
49 complications, Pediatric-inspired regimen, microbiologically documented infections

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69

## 70 **Introduction**

71 Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer but is relatively rare in  
72 adults, with an incidence of 1.7 cases per 100,000 annually in the total U.S. population [1]. Over  
73 the past few decades, the prognosis for pediatric ALL has significantly improved, with cure rates  
74 exceeding 90% using standard intensive multi-agent chemotherapy protocols [2, 3]. However,  
75 adult ALL remains associated with poorer outcomes, with only 40-50% survival at three years [4].  
76 This survival gap is likely due to differences in disease biology, treatment response, and patient-  
77 related factors.

78 Adolescents and young adults (AYAs), aged 15 to 39 years, face distinct treatment challenges due  
79 to their transitional physiology and a higher prevalence of high-risk disease features, resulting in  
80 event-free survival rates of 30-45% [5-7]. The presence of specific genetic factors, diversity within  
81 this age range, and different treatment protocols may contribute to the lower survival rates  
82 observed in adult ALL patients.

83 Multiple retrospective and prospective studies have demonstrated that pediatric-inspired regimens  
84 significantly improve survival outcomes in AYAs compared to standard adult regimens [8-10].  
85 Despite improved survival, infections remain a significant cause of morbidity and mortality,  
86 particularly during induction therapy, affecting over 30% of patients. Bacterial infections  
87 accounted for nearly 70% of infection-related deaths, while fungal infections accounted for about  
88 20% [11].

89 In Thailand, a study involving 107 ALL patients (67.3% received adult regimens and 32.7%  
90 received pediatric-inspired regimens) found that patients treated with pediatric-inspired protocols  
91 had better two-year disease-free survival (47.1% vs. 24.7%, hazard ratio [HR] 1.73, 95% CI 1.22–

92 3.03) and overall survival (50.8% vs. 31.2%, HR 1.52, 95% CI 0.83–2.78) compared to those  
93 treated with adult regimens [12]. Similarly, a multi-centre prospective study showed that AYAs  
94 had significantly higher two-year event-free survival compared to adults with ALL (45.5% vs  
95 26.2%;  $P < 0.019$ ) [13].

96 Despite evidence supporting pediatric-inspired regimens, the infection risks and associated factors  
97 in AYAs with ALL remain understudied, particularly when comparing pediatric-inspired and adult  
98 regimens in Thailand.

99

## 100 **Methods**

### 101 **Study design and Patients**

102 This retrospective cohort study included newly diagnosed adolescent and young adult patients with  
103 acute lymphoblastic leukemia (AYA-ALL), aged 15-40 years, treated at Chiang Mai University  
104 Hospital between 1 January 2007 and 31 December 2023. The diagnosis was confirmed according  
105 to the 2016 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues [14]. This  
106 study followed the Declaration of Helsinki and the International Conference on Harmonization  
107 Guidelines for Good Clinical Practice. The institutional ethical review board of the Faculty of  
108 Medicine, Chiang Mai University, Thailand, approved the study (study code: MED-2566-0630).  
109 Informed consent was waived due to the retrospective design and anonymized data collection.

110 Patients received induction chemotherapy using either a pediatric-inspired regimen (a modified  
111 Thai Pediatric Oncology Group [TPOG] protocol) [12, 15], a dosage and intensity-adjusted  
112 version of the Thai national childhood ALL protocol, or adult regimens (Hyper-CVAD or

113 GMALL) [16, 17]. Patients were excluded if they did not receive high-intensity chemotherapy,  
114 had Philadelphia chromosome-positive ALL and/or the *BCR::ABL1* fusion gene (detected via  
115 polymerase chain reaction), had incomplete clinical records, received induction therapy prior to  
116 referral, or had a known HIV infection. All patients received standard antimicrobial prophylaxis  
117 with trimethoprim/sulfamethoxazole for *Pneumocystis jirovecii* pneumonia (PJP) and acyclovir  
118 for herpes simplex virus (HSV) infections. Due to limited availability of mold-active antifungal  
119 agents, fluconazole was used for fungal prophylaxis. However, fluconazole and  
120 trimethoprim/sulfamethoxazole were withheld during certain treatment phases to prevent drug  
121 interactions. Granulocyte colony-stimulating factor (G-CSF) was routinely administered during  
122 induction and consolidation phases to reduce neutropenia-related infection risk. Notably, specific  
123 data on antimicrobial prophylaxis regimens for bacterial, fungal, and viral infections were not  
124 analyzed in this study.

## 125 **Data collection and outcomes**

126 Clinical data were retrospectively collected from electronic medical records with de-identified  
127 patients' data, potential bias from missing data. Data included baseline demographics, laboratory  
128 results, infectious events, and treatment outcomes. Infectious complications during all  
129 chemotherapy phases (induction, consolidation, and maintenance) were analyzed.

130 The primary outcome was the prevalence of infectious complications among AYA-ALL patients.  
131 The secondary outcomes were to identify associated risk factors for infectious complications and  
132 compare the infectious complications rate between patients receiving pediatric-inspired (TPOG)  
133 and adult regimens (Hyper-CVAD or GMALL).

134

## 135 **Definitions of infectious complications**

136 Infectious complications were categorized as follows:

- 137 • **Clinically Documented Infection (CDI):** Clinical signs and symptoms of infection  
138 without an identifiable pathogen.
- 139 • **Microbiologically Documented Infection (MDI):** Isolation of a pathogen from blood  
140 cultures or other infection sites.

141 Fever was defined as a body temperature  $>38.3^{\circ}\text{C}$  or a temperature  $>38^{\circ}\text{C}$  persisting for at least 1  
142 hour. Febrile neutropenia was defined as fever with an absolute neutrophil count (ANC)  $< 500/\mu\text{L}$   
143 [18].

## 144 **Sample size and statistical analysis**

145 Based on previous studies [9, 10], an infection prevalence of 50% was assumed in AYA-ALL  
146 patients. The required sample size was 97 patients, with a margin of error of 10% [19]. Continuous  
147 variables were reported as mean with standard deviation (SD) or median with interquartile range  
148 (IQR), depending on data distribution. Categorical variables were expressed as counts and  
149 percentages. Group comparisons for categorical data were performed using the chi-square test or  
150 Fisher's exact test. Continuous variables were compared using the Student's *t*-test or Mann-  
151 Whitney *U* test, as appropriate. Variables with a *p*-value  $< 0.1$  in univariate analysis were entered  
152 into a backward stepwise multivariate logistic regression model to identify independent risk factors  
153 for infections. Results were reported as odds ratios (OR) and 95% confidence intervals (CI).  
154 Statistical significance was set at *p*-value  $< 0.05$ . Patients with missing data were excluded. All

155 analyzes were performed using Microsoft Excel 2013 and STATA Version 17 (StataCorp, TX,  
156 USA) software.

157

## 158 **Results**

### 159 **Demographic and clinical characteristics**

160 A total of 124 newly diagnosed Philadelphia-negative ALL patients at Chiang Mai University  
161 Hospital between 1 January 2007 and 31 December 2023 were retrospectively reviewed, 30  
162 patients were excluded, and 94 AYA-ALL patients were recruited (**Fig 1**). The majority were male  
163 (62.8%,  $n = 59$ ), with a median age of 22.9 years (IQR 15-39.8). B-ALL was the most common  
164 subtype (58.8%). Of these, 56.4% ( $n = 53$ ) received pediatric-inspired TPOG regimen, while  
165 43.6% ( $n = 41$ ) received adult regimens (24 on Hyper-CVAD and 17 on GMALL). Overall, the  
166 median follow-up was 14.3 months (IQR 7.5-30.9). Relapse or refractory disease occurred in  
167 55.3% of patients, with a significantly higher rate in the adult regimen group compared to the  
168 TPOG group (68.3 % vs. 45.3,  $p = 0.02$ ). Only four patients (4.3%) underwent allogeneic stem cell  
169 transplantation (AlloSCT). Baseline characteristics were summarized in **Table 1**.

170

171 **Fig 1. Flow diagram demonstrated the recruitment alongside of inclusion and exclusion**  
172 **criteria**

173

174



175 **Table 1. Demographic and clinical characteristics of AYA-ALL patients**

Variables	All patients (n = 94)	TPOG (n = 53)	Adult regimen (n = 41)	p-value
Age, years	22.9 (15-39.8)	23.8(15-39.2)	21.7 (15-39.8)	0.63
Male, n (%)	59 (62.8)	36 (67.9)	23 (56.1)	0.24
ALL subtype, n (%)				0.31
B-ALL	55 (58.5)	31 (58.5)	24 (58.5)	
T-ALL	37 (39.4)	22 (41.5)	15 (36.6)	
N/A	2 (2.1)	0	2 (4.9)	
Hemoglobin, g/dL	9.5 (7.5-11.4)	9.5 (7.4-11.7)	9.1 (7.5-11.2)	0.60
WBC, / $\mu$ L	16600 (4500-47500)	23000 (5200-51400)	14170 (3570-39400)	0.40
Platelet, / $\mu$ L	75900 (32000-145000)	84000 (33000-158000)	65000 (32000-139000)	0.73
Peripheral blood blasts, %	49.5 (4-83)	48 (4.7-85)	50 (3-82)	0.82
Bone marrow blasts, %	90 (80-90)	90(80-90)	90(80-90)	0.12
Induction death, n (%)	4 (4.2)	2 (3.8)	2 (4.8)	1
Proceed to consolidation phase, n (%)	81 (86.1)	44 (83.0)	37 (90.2)	0.31
Duration of consolidation, days	223 (93-313)	261.5 (109.5- 398.5)	199 (66-245)	<0.01
Proceed to maintenance phase, n (%)	31 (32.9)	18 (33.9)	13 (31.7)	0.81
Duration of maintenance, days	721 (301-770)	731 (385-862)	516 (147-744)	0.16
Completed maintenance phase, n (%)	16 (51.6)	10 (55.5)	6 (46.1)	0.72
Relapse/Refractory, n (%)	52 (55.3)	24 (45.3)	28 (68.3)	0.02
Allogeneic SCT, n (%)	4 (4.3)	3 (5.7)	1 (2.4)	0.62

As the continuous data in this study did not follow a normal distribution, all data were reported as medians with interquartile ranges (IQR). WBC: white blood cell count, SCT: stem cell transplantation

176

177

178

179

180

## 181 Infectious outcomes

182 Infectious complications were reported in 79.8% (n = 75) of patients. Clinically documented  
183 infections (CDI) occurred in 61.7% (n = 58), and microbiologically documented infections (MDI)  
184 in 55.3% (n = 52). Bacterial infections were the most common (44.6%, n = 42), followed by fungal  
185 infections (19.1%, n = 18).

186 Patients on adult regimens experienced significantly more infectious complications than those on  
187 the TPOG regimen (90.2% vs. 71.7%,  $p = 0.03$ ), with higher CDI rates (73.4% vs. 52.8%,  $p =$   
188 0.04). Conversely, fungal infections were more frequent in the TPOG group (26.4% vs. 9.8%,  $p =$   
189 0.04) (**Table 2**).

190 **Table 2. Infectious complications among AYA-ALL patients based on treatment regimens**

Variables	All patients (n=94)	TPOG (n=53)	Adult regimen (n=41)	<i>p</i> -value
Overall infection, n (%)	75 (79.8)	38 (71.7)	37 (90.2)	0.03
CDI, n (%)	58 (61.7)	28 (52.8)	30 (73.2)	0.04
MDI, n (%)	52 (55.3)	28 (52.8)	24 (58.5)	0.58
Bacterial infection, n (%)	42 (44.6)	22 (41.5)	20 (48.8)	0.48
Fungus infection, n (%)	18 (19.1)	14 (26.4)	4 (9.8)	0.04

CDI: clinically documented infection, MDI: microbiologically documented infection

191  
192 Infection rates peaked during induction (47.8%) and consolidation (51.8%). During consolidation,  
193 infections were significantly higher in the adult regimen group compared to the TPOG group  
194 (64.9% vs. 40.9%,  $p = 0.03$ ) (**Fig 2**). MDI was most frequent in the TPOG group during induction  
195 (79% vs. 21%,  $p = 0.01$ ), whereas CDI was more common in the adult regimen group during the  
196 consolidation (69% vs. 30%,  $p < 0.01$ ) (**S1 Table**). Details of CDI based on treatment group and  
197 phase of treatment were provided (**S2 Table**).

198 **Fig 2. Number of infection based on treatment regimens and treatment phases**

199

200 **S1 Table. Number and types of infectious episodes (CDI and MDI) based on treatment**

201 **regimens and treatment phases**

202

203 **S2 Table. Clinically documented infection (CDI) based on treatment regimens and**

204 **treatment phases**

205

206 The most common infection sites for MDI were the bloodstream (40%), lung (24%) and the

207 genitourinary tract (16%) (**S3 Table**). Bacterial infections were the most prevalent (73%),

208 followed by fungal (24%) and viral (3%) infections. Gram-negative bacteria dominated (85%)

209 among bacterial pathogens, with *E. coli* (27%), *Salmonella spp.* (21%), and *Klebsiella spp.* (19%)

210 being the most prevalent. *Aspergillus spp.* was the most common fungal pathogen (**S4 Table and**

211 **S5 Table**). Induction-related mortality was 4.2% (n = 4), with septicemia causing death in 2

212 patients and hemorrhagic complications in 2 patients.

213 **S3 Table. Sites of microbiologically documented infection (MDI) based on treatment**

214 **regimens and treatment phases**

215 **S4 Table. Isolated pathogens of MDI in TPOG regimen group**

216 **S5 Table. Isolated pathogens of MDI in adult regimen group**

217

218

## 219 Risk factors for infectious complications

220 Multivariate logistic regression identified treatment with an adult regimen as a significant risk  
 221 factor for infectious complications among AYA-ALL patients (OR 3.55, 95% CI 1.02–12.36,  $p =$   
 222 0.04) (**Table 3**). For MDI, female sex (OR 3.88, 95% CI 1.41–10.68,  $p < 0.01$ ) and platelet counts  
 223 below 75,000 / $\mu$ L (OR 3.41, 95% CI 1.33–8.74,  $p = 0.01$ ) were independently associated with a  
 224 higher risk. In contrast, patients younger than 23 years (OR 0.33, 95% CI 0.12–0.85,  $p = 0.02$ ) and  
 225 those receiving only first-line treatment (OR 0.36, 95% CI 0.13–0.93,  $p = 0.03$ ) had a significantly  
 226 lower risk of MDI (**S6 Table**).

227

228 **Table 3. Univariate and multivariate analyses of risk factor for infectious complications**

Variables		Univariate			Multivariate		
		Infection (n=75)	Non infection (n=19)	$p$ -value	Odds ratio	95% CI	$p$ -value
Treatment regimens	Adults	37 (90.2)	4 (9.8)	0.026	3.55	1.02-12.36	0.04
	TPOG	38 (71.7)	15 (28.3)				
Sex	Female	30 (85.7)	5 (14.3)	0.2			
	male	45 (76.3)	14 (23.7)				
ALL type	B cell	44 (80)	8 (20.5)	0.95			
	others	31 (79.5)	11 (20.0)				
Relapse	yes	44 (84.6)	8 (15.4)	0.19			
	no	31 (73.8)	11 (26.2)				
1 <sup>st</sup> line of treatment	yes	39 (72.2)	15 (27.8)	0.03	0.4	0.11-1.40	0.155
	no	36 (90)	4 (10)				
Age, years	< 23	37 (78.7)	10 (21.3)	0.79			
	$\geq$ 23	38 (80.8)	9 (19.1)				
WBC, / $\mu$ L	<16600	40 (85.1)	7 (14.9)	0.19			

	$\geq 16600$	35 (74.5)	12 (25.5)				
Hb, g/dL	< 9.5	38 (80.9)	9 (19.1)	0.79			
	$\geq 9.5$	37 (78.7)	10 (21.3)				
Platelet, / $\mu$ L	<75000	39 (84.8)	7 (15.2)	0.23			
	$\geq 75000$	36 (75.0)	12 (25.0)				
PB blasts, %	<50%	42 (89.4)	5 (10.6)	0.02	3.41	1.05-11.04	0.04
	$\geq 50\%$	33 (70.2)	14(29.8)				
BM blasts, %	<90%	34 (79.0)	9 (20.9)	0.87			
	$\geq 90\%$	41 (80.4)	10 (19.6)				

WBC: white blood cell count, Hb: hemoglobin, PB: peripheral blood, BM: bone marrow

229

230 **S6 Table. Univariate and multivariate analyses of risk factor for MDI**

## 231 **Discussion**

232 This study demonstrated a high incidence of infectious complications in AYA-ALL patients, with  
 233 79.8% experiencing infections. Clinically documented infections (CDI) occurred in 61.7% of  
 234 patients, and microbiologically documented infections (MDI) in 55.3%. These rates are  
 235 comparable to studies from Taiwan and Mexico, which reported infection rates of approximately  
 236 87% in ALL patients receiving intensive chemotherapy [20, 21]. Similarly, an Italian study  
 237 highlighted infectious complications as a leading cause of morbidity in AYA-ALL patients,  
 238 underscoring the importance of infection prevention strategies [22].

## 239 **Phase-specific infection risk**

240 Infection rates were highest during the induction (47.8%) and consolidation (51.8%) phases,  
 241 aligning with findings from MD Anderson, which reported infection rates of 22% and 63% during

242 these phases, respectively [9]. The increased risk during induction is likely due to the intensive  
243 chemotherapy and high-dose steroids, causing severe myelosuppression and immune suppression.  
244 During consolidation, cumulative immunosuppression further elevates infection risk. Differences  
245 in regimen intensity between TPOG and adult protocols may explain the observed variation in  
246 infection rates, highlighting the need for phase-specific supportive care.

## 247 **Fungal infection in the TPOG group**

248 Fungal infections were more frequent in patients receiving the TPOG regimen (26.4%) compared  
249 to those on adult regimens (9.8%), consistent with findings from Mexico, where 20% of ALL  
250 patients developed fungal infections [21]. This increased risk in the TPOG group may result from  
251 higher steroid doses and longer chemotherapy durations, which prolong immunosuppression and  
252 impair both humoral and cellular immunity. Additionally, fluconazole was used for antifungal  
253 prophylaxis due to limited access to mold-active agents at our center, potentially contributing to  
254 the higher rates of *Aspergillus* infections. In contrast, studies from Saudi Arabia reported lower  
255 fungal infection rates with micafungin or anidulafungin prophylaxis [23]. Environmental factors,  
256 particularly in tropical climates, may also increase fungal exposure [24].

## 257 **Bacterial infections predominate in adult regimens**

258 Gram-negative bacteria were the most common pathogens (85%), with *E. coli* (27%)  
259 and *Salmonella* spp. (21%) being the most prevalent. These findings align with studies from Italy,  
260 where gram-negative organisms were predominant in leukemia patients [25]. Patients on adult  
261 regimens experienced significantly more bacterial infections, likely due to prolonged and severe  
262 neutropenia associated with these protocols.

## 263 **Risk factors for infection**

264 Multivariate analysis identified treatment with adult regimens as a significant risk factor for overall  
265 infections (OR 3.55;  $p = 0.04$ ). Female gender (OR 3.88;  $p < 0.01$ ) and platelet counts below  
266 75,000/ $\mu\text{L}$  (OR 3.41;  $p = 0.01$ ) were independent risk factors for MDI. Conversely, younger  
267 patients ( $<23$  years) and those receiving first-line treatment had a lower infection risk. The higher  
268 infection rate in females may be due to a higher incidence of urinary tract infections, as reported  
269 in other studies [20].

## 270 **Clinical implications**

271 These findings emphasize the need for tailored infection prevention strategies based on treatment  
272 regimen and phase. For patients receiving pediatric-inspired regimens, particularly TPOG, the use  
273 of mold-active antifungal prophylaxis should be considered. Patients on adult regimens may  
274 benefit from more aggressive bacterial infection prevention and early intervention during  
275 neutropenic episodes. Environmental and regional factors must also be considered when designing  
276 infection control protocols.

## 277 **Study limitations**

278 This study has several limitations that should be considered when interpreting the findings. Its  
279 retrospective design may introduce selection bias, and incomplete or inconsistent medical records  
280 could affect data accuracy. The relatively small sample size and single-center setting limit the  
281 generalizability of the results to broader populations and other healthcare settings. Additionally,  
282 the study did not analyze antimicrobial resistance patterns, which could impact the interpretation  
283 of infection outcomes. Variations in antimicrobial prophylaxis regimens for bacterial, fungal, and

284 viral infections were also not fully assessed, potentially influencing infection rates. These  
285 limitations highlight the need for larger, multi-center prospective studies to validate these findings  
286 and optimize infection prevention strategies in AYA-ALL patients.

287

## 288 **Conclusions**

289 Our study highlights the high burden of infectious complications in AYA-ALL patients,  
290 particularly those receiving adult chemotherapy regimens. Fungal infections were notably more  
291 common in patients treated with pediatric-inspired regimens, likely due to prolonged steroid use  
292 and insufficient mold-active antifungal prophylaxis. These findings underscore the need for  
293 targeted infection prevention and early intervention strategies to improve outcomes in this  
294 vulnerable population.

295

## 296 **Supporting information**

297 **S1-6 File.** The table S1 to S6 (S1-6\_Table.docx)

298 **S1 Table.** Number and types of infectious episodes (CDI and MDI) based on treatment regimens  
299 and treatment phases

300 **S2 Table.** Clinically documented infection (CDI) based on treatment regimens and treatment  
301 phases

302 **S3 Table.** Sites of microbiologically documented infection (MDI) based on treatment regimens  
303 and treatment phases



304 **S4 Table.** Isolated pathogens of MDI in TPOG regimen group

305 **S5 Table.** Isolated pathogens of MDI in adult regimen group

306 **S6 Table.** Univariate and multivariate analyses of risk factor for MDI

307

## 308 **Acknowledgements**

309 I would like to express my sincere gratitude to all the staff at the Division of Hematology,  
310 Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, for their invaluable  
311 support and dedication to patient care throughout this study.

## 312 **Conflict of Interest Statement**

313 The author(s) have declared that no potential conflicts of interest relevant to this article

## 314 **Funding Sources**

315 There was no funding in this study.

## 316 **Ethics Statement**

317 The study was conducted in accordance with the International Conference on Harmonization for  
318 Good Clinical Practice guidelines and the 1964 Declaration of Helsinki. The study was approved  
319 by the the institutional ethical review board of the Faculty of Medicine, Chiang Mai University,  
320 Thailand (study code: MED-2566-0630). Informed consent was waived due to the retrospective  
321 design and anonymized data collection.

322

## 323 **Author's contributions:**

324 Conceptualization: Thanawat Rattanathamthee

325 Methodology: Thanawat Rattanathamthee

326 Data curation: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

327 Formal analysis: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

328 Investigation: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

329 Writing-Original draft: Thanawat Rattanathamthee, Phoutthasin Vongngakesone

330 Writing- review and editing: All authors

331

## 332 **Data Availability Statement**

333 The datasets generated during and/or analyzed in the current study, containing potentially  
334 sensitive patient information and de-identified patient data, are available through the research  
335 administration section of the Faculty of Medicine at Chiang Mai University, Thailand. (email:  
336 [researchmed@cmu.ac.th](mailto:researchmed@cmu.ac.th))

337

338

339

340

341

342

343

344

345

## 346 **References**

- 347 1. Surveillance, Epidemiology, and End Results Program (SEER) Cancer Stat Facts:  
348 Leukemia - Acute Lymphocytic leukemia (ALL). National Cancer Institute. Bethesda, MD  
349 [Available from: <https://seer.cancer.gov/statfacts/html/aly1.html>]. Accessed 18 January 2025.
- 350 2. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What  
351 determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia  
352 treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and  
353 Leukemia Group B studies. *Blood*. 2008;112(5):1646-54.
- 354 3. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *N Engl J Med*.  
355 2015;373(16):1541-52.
- 356 4. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of  
357 treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. *J*  
358 *Clin Oncol*. 2000;18(3):547-61.
- 359 5. Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and  
360 young adults. *Blood*. 2015;125(24):3702-10.
- 361 6. Roberts KG. Genetics and prognosis of ALL in children vs adults. *Hematology Am Soc*  
362 *Hematol Educ Program*. 2018;2018(1):137-45.
- 363 7. Tran TH, Tasian SK. How I treat Philadelphia chromosome-like acute lymphoblastic  
364 leukemia in children, adolescents, and young adults. *Blood*. 2025;145(1):20-34.
- 365 8. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M, Swedish Adult Acute  
366 Lymphocytic Leukemia G, et al. Treatment outcome in young adults and children >10 years of

- 367 age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and  
368 an adult protocol. *Cancer*. 2006;107(7):1551-61.
- 369 9. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, et al. Final  
370 results of a single institution experience with a pediatric-based regimen, the augmented Berlin-  
371 Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and  
372 comparison to the hyper-CVAD regimen. *Am J Hematol*. 2016;91(8):819-23.
- 373 10. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric  
374 regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of  
375 CALGB 10403. *Blood*. 2019;133(14):1548-59.
- 376 11. O'Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al. Infection-related mortality  
377 in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.  
378 *Blood*. 2014;124(7):1056-61.
- 379 12. Tantiworawit A, Rattanathammethee T, Chai-Adisaksopha C, Rattarittamrong E,  
380 Norasetthada L. Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired  
381 regimens: a single-center experience. *Int J Hematol*. 2019;110(3):295-305.
- 382 13. Limvorapitak W, Owattanapanich W, Utchariyaprasit E, Niparuck P, Puavilai T,  
383 Tantiworawit A, et al. Better survivals in adolescent and Young adults, compared to adults with  
384 acute lymphoblastic leukemia - A multicenter prospective registry in Thai population. *Leuk Res*.  
385 2019;87:106235.
- 386 14. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016  
387 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.  
388 *Blood*. 2016;127(20):2391-405.

- 389 15. Seksarn P, Wiangnon S, Veerakul G, Chotsampancharoen T, Kanjanapongkul S,  
390 Chainansamit SO. Outcome of Childhood Acute Lymphoblastic Leukemia Treated Using the Thai  
391 National Protocols. *Asian Pac J Cancer Prev*. 2015;16(11):4609-14.
- 392 16. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading  
393 prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic  
394 leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase  
395 chain reaction analysis. *Blood*. 2002;99(5):1536-43.
- 396 17. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up  
397 results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone  
398 (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. *Cancer*.  
399 2004;101(12):2788-801.
- 400 18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice  
401 guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by  
402 the infectious diseases society of america. *Clin Infect Dis*. 2011;52(4):e56-93.
- 403 19. Naing L, Nordin RB, Abdul Rahman H, Naing YT. Sample size calculation for prevalence  
404 studies using Scalex and ScalaR calculators. *BMC Med Res Methodol*. 2022;22(1):209.
- 405 20. Li MJ, Chang HH, Yang YL, Lu MY, Shao PL, Fu CM, et al. Infectious complications in  
406 children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group  
407 protocol: A 16-year tertiary single-institution experience. *Pediatr Blood Cancer*. 2017;64(10).
- 408 21. Inclan-Alarcon SI, Riviello-Goya S, Teran-De-la-Sancha K, Fierro-Angulo OM, Acosta-  
409 Medina AA, Demichelis-Gomez R, et al. Induction-related mortality in adolescents and young

410 adults with acute lymphoblastic leukemia in a resource-limited setting: do treatment-related  
411 complications create more impact than disease biology? *Blood Res.* 2022;57(1):29-33.

412 22. Zappasodi P, Calabretta L, Lazzarotto D, Cerrano M, Fracchiolla N, Papayannidis C, et al.  
413 Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic  
414 Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol. *Blood.*  
415 2023;142(Supplement 1):5877-.

416 23. Salama H, Eldadah S, Omer MH, Alhejazi A, Bin Dayil L, Almozaini A, et al. Comparison  
417 of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults  
418 with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.  
419 *Leuk Res.* 2023;130:107316.

420 24. Tang JL, Kung HC, Lei WC, Yao M, Wu UI, Hsu SC, et al. High Incidences of Invasive  
421 Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy  
422 without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. *PLoS*  
423 *One.* 2015;10(6):e0128410.

424 25. Offidani M, Corvatta L, Malerba L, Marconi M, Leoni P. Infectious complications in adult  
425 acute lymphoblastic leukemia (ALL): experience at one single center. *Leuk Lymphoma.*  
426 2004;45(8):1617-21.




Figure2

124 newly diagnosed Philadelphia-negative ALL patients  
(1 January 2007 to 31 December 2023)

**Exclusion criteria**

- 25 age at diagnosis > 40 years
- 2 not receiving chemotherapy
- 3 missing data

94 Philadelphia-negative AYA-ALL patients  
met **inclusion criteria**

Figure 1